

1 Estimation of SARS-CoV-2 emissions from non-symptomatic cases

2 A.A.Prof. Dr. Michael Riediker¹, Dr. Dai-Hua Tsai^{1,2}

3 1 Swiss Centre for Occupational and Environmental Health, Winterthur, Switzerland

4 2 Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of

5 Psychiatry Zurich, University of Zurich, Zurich, Switzerland

6 Key Points

7 **Question:** How much SARS-CoV-2 virus is released from a case by breathing and coughing,
8 and what is the resulting concentration in a room?

9 **Finding:** Both, breathing and coughing are predicted to release large numbers of viruses,
10 which can lead to billions of virus copies/m³ in a poorly ventilated room with a coughing
11 emitter.

12 **Meaning:** These results may explain the high rate of transmissions and implies the need for
13 strict respiratory protection when people are in the same room with a COVID-19 case.

14 Word counts:

15 Abstract: 272, Manuscript: 1801, Tables: 1, Figures: 3

16 Address for correspondence

17 Michael Riediker

18 michael.riediker@alumni.ethz.ch

19 Swiss Centre for Occupational and Environmental Health (SCOEH)

20 Binzhoferstrasse 87, CH-8404 Winterthur, Switzerland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Abstract

22 **Importance:** Cases of the coronavirus disease 2019 (COVID-19) with no or mild symptoms
23 were reported to frequently transmit the disease even without direct contact. The severe
24 acute respiratory syndrome virus (SARS-COV-2) was found at very high concentrations in
25 swab and sputum of such cases.

26 **Objective:** We aimed to estimate virus release from such cases into different aerosol sizes by
27 normal breathing and coughing, and what exposure can result from this in a room shared
28 with such as case.

29 **Data Sources and Model:** We combined the size-distribution of exhaled breath aerosols for
30 coughing and normal breathing with viral sputum concentrations as approximation for lung
31 lining liquid to obtain an estimate of emitted virus levels. The resulting emission data fed a
32 single-compartment model of airborne concentrations in a room of 50m³, the size of a small
33 office or medical exam room.

34 **Results:** The estimated viral load in aerosols emitted by patients while breathing normally
35 was on average 0.34 copies/cm³ and could go up to 11.5 copies/cm³. The corresponding
36 numbers for coughing patients were 10,900 copies/cm³ and 366,000 copies/cm³,
37 respectively, per cough. The resulting concentrations in a room with a coughing emitter
38 were always very high, up to 2.02*10⁹ copies/m³. However, also regular breathing aerosol
39 from high emitters was predicted to lead to several thousand copies/m³.

40 **Conclusions and Relevance:** These very high predicted virus concentrations may provide an
41 explanation why for COVID-19, frequent community transmissions from non-symptomatic
42 cases and also high infection rates in medical staff in hospital settings were reported. Our
43 findings suggest that strict respiratory protection is needed when there is a chance to be in

44 the same room with a patient - whether symptomatic or not - especially if this was for a
45 prolonged time.

46 Introduction

47 The novel Coronavirus disease 2019 (COVID-19), emerged in late 2019 in Wuhan, China ¹
48 from where it spread to the entire world. COVID-19 is caused by a novel type of Coronavirus,
49 the severe acute respiratory syndrome virus (SARS-CoV-2) ². The host-receptor for SARS-
50 CoV-2 was found to be Angiotensin I converting enzyme 2 (ACE2), which is present in cells of
51 the lungs and airways ³. A large number of patients hospitalized for other reasons and also
52 an important proportion of the medical staff contracted COVID-19 ⁴. This is remarkable given
53 that medical professionals are trained at protecting themselves against infections. Also a
54 series of community-transmissions were reported from cases that had no apparent
55 symptoms, some even without direct contact ⁵⁻⁸. Correspondences about the viral load in
56 samples from COVID-19 patients having no or only mild symptoms reported very high
57 concentrations of SARS-CoV-2 in swab samples ⁸⁻¹⁰. This raised the question whether
58 transfections could occur via the air.

59 When coughing, humans release thousands of aerosol droplets per cubic-centimeter in the
60 size range of 0.6 to 15 μm , with the droplet concentration increasing strongly with cough
61 flow rate ¹¹. But also normal breathing will lead to some aerosol production, which is
62 attributed to fluid film rupture in the respiratory bronchioles during inhalation leading to the
63 formation of droplets that are released during exhalation ¹². The size of these droplets is
64 mostly below 1 μm ¹³. The mode of droplet generation implies that they consist of lung lining
65 liquid including dispersed viruses. Indeed, human volunteers exposed to virus-sized
66 nanoparticles show nano-scaled particles in their exhaled breath ^{14,15}. Also, the described

67 size distribution of particles emitted from coughing as well as normal respiration suggests
68 that an important proportion of them will be able to remain airborne for many hours in
69 turbulent conditions ¹⁶.

70 Objectives

71 This study aimed to estimate the cumulative viral load released from COVID-19 patients with
72 no to moderate symptoms in different aerosol sizes via respiration and coughing. We then
73 used this information to make a risk appraisal for the situation of a high emitter that is either
74 breathing normally or coughing in a room operated at different air exchange rates. We
75 chose a room size that is similar to a medical examination room or an office shared by two
76 to three people.

77 Design and Methods

78 Concept:

79 The release of viruses from individual patients was modeled by first calculating the viral load
80 per exhaled droplets formed during normal breathing and while coughing. The resulting size-
81 distribution provided an initial estimate of the concentration of SARS-CoV-2 virus copies
82 released by a regularly breathing or coughing patient. This viral emission factor was then fed
83 into a well-mixed one-compartment model to simulate the situation in a closed room with
84 different ventilation air exchange rates.

85 Data sources:

86 Data on the number of viral copies present in sputum was used to estimate the SARS-CoV-2
87 viral load present in the lining liquid of respiratory bronchioles in patients ⁹, specifically an
88 average of 7×10^6 copies/ml with a maximum of 2.35×10^9 copies/ml (hereafter referred to

89 as "high emitters"), and 1,000 copies/ml representing a low-virus producing patient ("low
90 emitters").

91 Exhaled aerosol size distributions and numbers were retrieved from published studies on
92 coughing¹¹ and healthy persons¹². Both studies assessed the size-number distribution of
93 freshly emitted aerosols. The concentration of viral copies in each aerosol size was
94 calculated from the volume of the aerosols, the actual count number in each size and the
95 above-mentioned virus-load per ml sputum. The viral load in the actual aerosol counts in
96 each aerosol size was then used to calculate the total viral concentration. The cumulative
97 emissions in the PM₁₀ fraction were summed up after applying the standard size
98 fractionation curves¹⁷ to the aerosol distribution.

99 **Model:**

100 A one-compartment model estimated the virus load concentration C for a perfectly mixed
101 room of volume V_R of 50 m³ with one patient as source, using the following mass-balance
102 (equation 1):

$$103 \quad V_R * \frac{dC}{dt} = c_{PM10} * RR * V_t - \frac{V_R}{ER} * C(t) - \frac{\ln(2) * V_R}{t_{1/2}} * C(t) \quad (1)$$

104 The emission rate was calculated from the concentration c_{PM10}, the viral load in the PM₁₀-
105 size range, which are particles collected with a 50% efficiency cut-off at 10 µm aerodynamic
106 diameter; and a respiratory rate of 15 breaths per minute (RR) at a tidal volume of V_t of 500
107 ml per breath. Air exchange rates (ER) used were 1-, 3-, 10- and 20-times per hour. The virus'
108 half-life t_{1/2} of 1.1 hours was obtained from an experimental study about the persistence of
109 SARS-CoV-2 on surfaces and when airborne¹⁸, tested by assessing the 50% tissue culture
110 infective dose (TCID₅₀).

111 The model for coughing was identical, except that coughing was assumed to happen every
112 30 seconds at a volume of 250 ml.

113 All statistics and models were calculated using Stata/SE 15.1 (Mac 64-bit Intel, Rev. 03 Feb
114 2020, StataCorp, College Station, TX, USA).

115 Results

116 Emissions from normal breathing patients

117 To estimate the virus emissions from patients breathing normally, we first calculated the
118 viral load for the aerosol size distribution. Figure 1 shows that the highest virus load is
119 present in the largest aerosol size. The cumulative total emission per breath was 0.34
120 copies/cm³(air) for an average patient, and 11.5 copies/cm³ for high emitters. The
121 cumulative emissions in the PM₁₀ fraction were about 1/3 of these values with 0.12
122 copies/cm³ (average) and 4.1 copies/cm³ (high) per breath.

123 Emission from coughing patient

124 We then estimated the virus emissions from a coughing patient (Figure 2). The cumulative
125 total emission per cough was 19,400 copies/cm³ for an average patient, and 651,315
126 copies/cm³ for high emitters. The cumulative emissions in the PM₁₀ fraction were about 1/2
127 of these values with 10,900 copies/cm³ (average) and 366,000 copies/cm³ (high) per cough.

128 Exposure estimation for bystanders

129 To estimate the exposure of bystanders spending time in the same room as a COVID-19
130 positive person, we calculated the time-course of the viral load in the thoracic size fraction
131 for aerosols released from a high-emitter either breathing normally or coughing. Figure 3
132 shows the results for a high-emitting patient coughing frequently.

133 For a typical hospital ventilation situation of 10 air exchanges per hour, the concentration
134 plateaus after about 30 minutes, while for a typical office with 3 air exchanges/hour,
135 concentrations continue to rise for almost three hours. In the used model, concentrations
136 scale linearly with the patient emission rate, the plateau concentrations for different
137 emitting patients and ventilation types are summarized in Table 1.

138 Discussion

139 An elevated number of viruses is expected to be released by COVID-19 patients in the form
140 of airborne aerosols, especially when they are coughing. While the bigger portion of the
141 emitted viral load is in the form of large particles that can deposit rapidly, there is also an
142 important portion in the smaller size fractions. Small aerosols can remain airborne for an
143 extended time ¹⁶ and are very effective at reaching the deeper regions of the lungs.

144 An average person breathes about a half m³ per hour in resting state ¹⁹, which can rapidly
145 increase to several m³ during exercise ²⁰. Thus, a person spending time in a room with an
146 average emitting patient breathing normally has a realistic chance of inhaling tens to
147 hundreds of copies of the virus even when keeping distance from that person. The situation
148 is worse in the presence of a high emitter and worst if the patient is a coughing high emitter.

149 A review of a wide range of respiratory viruses suggests that the infective dose is often quite
150 low. Sometimes as few as few hundred units of active virus (TCID₅₀) ²¹ seem sufficient to
151 provoke a disease. Thus, our modelling suggests that there is a clear risk of infections for a
152 person spending an extended time in the room with an infected person, even if the distance
153 is too large for direct transmission. The situation is worse if the person is coughing.

154 The very high virus load in exhaled respiratory aerosols proposed by our assessment may be
155 an explanation why COVID-19 was associated with much more transfections to hospital staff

156 than what was expected from SARS⁴. While having everybody wear a surgical face mask can
157 be an effective source control²², the protective factors may still be insufficient if an
158 extended amount of time is spent in the same room, especially if the room is small and the
159 ventilation low. Increasing ventilation can help to some extent but is not sufficient in a room
160 of the size of a typical office or medical exam room. Note also that ventilation design for
161 hospitals is complex and not always functioning as intended²³.

162 What are the implications for the normal life and the workplace?

- 163 • The risk of infection is real when being near an infected person in a room for more
164 than a few minutes and this even when keeping distance to that person.
- 165 • Sharing a workplace in a small room with a non-symptomatic case seems not
166 advised. This implies that workplaces should not be shared as long as there are no
167 rapid tests to differentiate between healthy and non-symptomatic cases.
- 168 • Medical staff is advised to wear the best possible respiratory protection whenever in
169 the same room as a patient, especially when this person is coughing.
- 170 • In addition, every patient, also non-symptomatic ones, should wear a well-fitting
171 surgical face mask to reduce emissions, which will increase the overall protection for
172 the medical staff.

173 Our assessment has a number of limitations. Namely:

- 174 • The estimated virus levels strongly depend on the number of virus copies produced
175 by a COVID-19 case. We used sputum data from a well described peer-reviewed
176 study⁹ assuming that it is a reasonable approximation for the virus load in the
177 respiratory bronchioles, the space where most respiratory aerosols are formed. Our

178 high-emitter estimates would be 100-fold higher if the most extreme

179 correspondence data was used ¹⁰.

180 • We used information about virus copies but compare the results with TCID₅₀ infective

181 dose. Research on other virus types suggests that the number of virus copies and

182 TCID₅₀ are comparable ²⁴. However, it would be important to confirm this

183 relationship for the case of SARS-CoV-2.

184 • For breath aerosols release, we used data reported for normal breathing young

185 healthy subjects. However, aerosol formation is influenced by surface tension of the

186 lung lining liquid ²⁵. It is likely that aerosol formation will be altered in COVID-19

187 positive cases but it is not clear in which direction.

188 • Aerosol droplet will shrink in dry air ²⁶, resulting in a shift to smaller particle sizes.

189 This will not directly change the number of copies in the PM₁₀ range but simply

190 upconcentrate the viral load per aerosol. While we addressed passivation of viruses

191 in the air by using the documented half-life ¹⁸, it is still possible that viruses in smaller

192 droplets are quicker passivated because of shorter diffusion distances for airborne

193 oxidants and faster increasing salinity. Our estimates would be slightly smaller if this

194 was relevant.

195 Acknowledgments

196 This modelling was entirely funded by the Swiss Centre for Occupational and Environmental

197 Health (SCOEH).

198 References

- 199 • 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with
200 Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733.
201 doi:10.1056/NEJMoa2001017
- 202 • 2. Gorbalenya AE, Baker SC, Baric RS, et al. *Severe Acute Respiratory Syndrome-*
203 *Related Coronavirus: The Species and Its Viruses – a Statement of the Coronavirus Study*
204 *Group*. Microbiology; 2020. doi:10.1101/2020.02.07.937862
- 205 • 3. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues
206 identify cell types and receptors of human coronaviruses. *Biochem Biophys Res*
207 *Commun*. March 2020:S0006291X20305234. doi:10.1016/j.bbrc.2020.03.044
- 208 • 4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients
209 With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*.
210 2020;323(11):1061. doi:10.1001/jama.2020.1585
- 211 • 5. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of
212 COVID-19. *JAMA*. February 2020. doi:10.1001/jama.2020.2565
- 213 • 6. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic
214 SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King
215 County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(13):377-
216 381. doi:10.15585/mmwr.mm6913e1

- 217 • 7. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the
218 rapid dissemination of novel coronavirus (SARS-CoV2). *Science*. March 2020.
219 doi:10.1126/science.abb3221
- 220 • 8. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory
221 Specimens of Infected Patients. *N Engl J Med*. 2020;382(12):1177-1179.
222 doi:10.1056/NEJMc2001737
- 223 • 9. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of
224 hospitalized patients with COVID-2019. *Nature*. April 2020. doi:10.1038/s41586-020-
225 2196-x
- 226 • 10. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical
227 samples. *Lancet Infect Dis*. 2020;20(4):411-412. doi:10.1016/S1473-3099(20)30113-4
- 228 • 11. Yang S, Lee GWM, Chen C-M, Wu C-C, Yu K-P. The Size and Concentration of
229 Droplets Generated by Coughing in Human Subjects. *J Aerosol Med*. 2007;20(4):484-
230 494. doi:10.1089/jam.2007.0610
- 231 • 12. Johnson GR, Morawska L. The Mechanism of Breath Aerosol Formation. *J*
232 *Aerosol Med Pulm Drug Deliv*. 2009;22(3):229-237. doi:10.1089/jamp.2008.0720
- 233 • 13. Papineni RS, Rosenthal FS. The Size Distribution of Droplets in the Exhaled
234 Breath of Healthy Human Subjects. *J Aerosol Med*. 1997;10(2):105-116.
235 doi:10.1089/jam.1997.10.105

- 236 • 14. Gschwind S, Graczyk H, Günther D, Riediker M. A method for the preservation
237 and determination of welding fume nanoparticles in exhaled breath condensate. *Env*
238 *Sci Nano*. 2016;3(2):357–364. doi:10.1039/C5EN00240K
- 239 • 15. Sauvain J-J, Hohl MSS, Wild P, Pralong JA, Riediker M. Exhaled breath
240 condensate as a matrix for combustion-based nanoparticle exposure and health effect
241 evaluation. *J Aerosol Med Pulm Drug Deliv*. 2014;27(6):449–458.
242 doi:10.1089/jamp.2013.1101
- 243 • 16. Willeke K, Baron PA, eds. *Aerosol Measurement: Principles, Techniques, and*
244 *Applications*. New York: Van Nostrand Reinhold; 1993.
- 245 • 17. BSI. *EN 481:1993 Workplace Atmospheres. Size Fraction Definitions for*
246 *Measurement of Airborne Particles*. BSI; 1993.
- 247 • 18. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability
248 of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*. March
249 2020;NEJMc2004973. doi:10.1056/NEJMc2004973
- 250 • 19. Beardsell I, ed. *Get through MCEM. Part A: MCQs*. London: RSM; 2011.
- 251 • 20. Ramos CA, Reis JF, Almeida T, Alves F, Wolterbeek HT, Almeida SM. Estimating
252 the inhaled dose of pollutants during indoor physical activity. *Sci Total Environ*.
253 2015;527-528:111-118. doi:10.1016/j.scitotenv.2015.04.120
- 254 • 21. Yezli S, Otter JA. Minimum Infective Dose of the Major Human Respiratory
255 and Enteric Viruses Transmitted Through Food and the Environment. *Food Environ*
256 *Viro*. 2011;3(1):1-30. doi:10.1007/s12560-011-9056-7

- 257 • 22. Patel RB, Skaria SD, Mansour MM, Smaldone GC. Respiratory source control
258 using a surgical mask: An *in vitro* study. *J Occup Environ Hyg*. 2016;13(7):569-576.
259 doi:10.1080/15459624.2015.1043050
- 260 • 23. Grosskopf KR, Herstein KR. The aerodynamic behavior of respiratory aerosols
261 within a general patient room. 2012;18(4):15.
- 262 • 24. Kim J-O, Kim W-S, Kim S-W, et al. Development and Application of
263 Quantitative Detection Method for Viral Hemorrhagic Septicemia Virus (VHSV)
264 Genogroup IVa. *Viruses*. 2014;6(5):2204-2213. doi:10.3390/v6052204
- 265 • 25. Edwards DA, Man JC, Brand P, et al. Inhaling to mitigate exhaled bioaerosols.
266 *Proc Natl Acad Sci*. 2004;101(50):17383-17388. doi:10.1073/pnas.0408159101
- 267 • 26. Holmgren H, Bake B, Olin A-C, Ljungström E. Relation Between Humidity and
268 Size of Exhaled Particles. *J Aerosol Med Pulm Drug Deliv*. 2011;24(5):253-260.
269 doi:10.1089/jamp.2011.0880

270

271 [Figure legends](#)

272 Figure 1: Size distribution of exhaled aerosols (left) during normal respiration and resulting
273 viral emissions per breath (right) for average (red), high and low emitters (spike-lines) per
274 aerosol size.

275 Figure 2: Size distribution of exhaled aerosols (left) during coughing and resulting viral
276 emissions per breath (right) with average (red), high and low emitters (spike-lines) per
277 aerosol size.

278 Figure 3: Temporal course of airborne virus load in a perfectly mixed room of 50 m³ for
279 different air exchange rates. The emitter has a high virus-load in the lungs and is coughing
280 intermittently.

281 Tables

282 Table 1: Plateau concentration for different combinations of air exchange rate, emission form and emitter type.

Air exchange rate (times/ hour)	1 / hour	3 / hour	10 / hour	20 / hour
Time until 99% of plateau	169 minutes	77 minutes	26 minutes	14 minutes
Airborne viral concentration at plateau (copies/m³)				
Regular breathing				
Low emitter	0.0096	0.0043	0.0015	0.0008
Average emitter	44.80	20.18	6.87	3.54
High emitter	22,554	10,100	3,458	1,782
Frequent coughing				
Low emitter	859	386	132	67.9
Average emitter	4,010,000	1,800,000	615,000	317,000
High emitter	2.02e+09	9.06e+08	3.10e+08	1.60e+08

283

Figure 1





Figure 2





Figure 3

